CN110869388B - 用于肿瘤特异性细胞消耗的Fc优化的抗CD25 - Google Patents

用于肿瘤特异性细胞消耗的Fc优化的抗CD25 Download PDF

Info

Publication number
CN110869388B
CN110869388B CN201880018976.8A CN201880018976A CN110869388B CN 110869388 B CN110869388 B CN 110869388B CN 201880018976 A CN201880018976 A CN 201880018976A CN 110869388 B CN110869388 B CN 110869388B
Authority
CN
China
Prior art keywords
antibody
seq
cells
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880018976.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN110869388A (zh
Inventor
安妮·古比耶
帕斯卡·梅希尔
约瑟芬·萨利姆
贝特里兹·古耶内切亚·科尔佐
凯文·莫尔德
塞尔吉奥·克萨达
卡尔·佩格斯
弗雷德·阿尔斯·瓦尔加斯
伊莎贝尔·索罗蒙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Task Therapy Co ltd
Cancer Research Technology Ltd
Original Assignee
Task Therapy Co ltd
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61655786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN110869388(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1710879.6A external-priority patent/GB201710879D0/en
Priority claimed from GBGB1714429.6A external-priority patent/GB201714429D0/en
Application filed by Task Therapy Co ltd, Cancer Research Technology Ltd filed Critical Task Therapy Co ltd
Publication of CN110869388A publication Critical patent/CN110869388A/zh
Application granted granted Critical
Publication of CN110869388B publication Critical patent/CN110869388B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201880018976.8A 2017-03-17 2018-03-13 用于肿瘤特异性细胞消耗的Fc优化的抗CD25 Active CN110869388B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP17161717 2017-03-17
EP17161717.8 2017-03-17
GBGB1710879.6A GB201710879D0 (en) 2017-07-06 2017-07-06 Methods and compounds for tumour-specific cell depletion
GB1710879.6 2017-07-06
GBGB1714429.6A GB201714429D0 (en) 2017-09-07 2017-09-07 Compounds and methods for tumour-specific cell depletion
GB1714429.6 2017-09-07
PCT/EP2018/056312 WO2018167104A1 (en) 2017-03-17 2018-03-13 Fc-optimized anti-cd25 for tumour specific cell depletion

Publications (2)

Publication Number Publication Date
CN110869388A CN110869388A (zh) 2020-03-06
CN110869388B true CN110869388B (zh) 2024-09-20

Family

ID=61655786

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880018976.8A Active CN110869388B (zh) 2017-03-17 2018-03-13 用于肿瘤特异性细胞消耗的Fc优化的抗CD25

Country Status (26)

Country Link
US (1) US11879014B2 (https=)
EP (1) EP3596123B1 (https=)
JP (2) JP2020514363A (https=)
KR (1) KR20190130137A (https=)
CN (1) CN110869388B (https=)
AU (1) AU2018233976B2 (https=)
BR (1) BR112019017017A2 (https=)
CA (1) CA3056506A1 (https=)
CL (1) CL2019002624A1 (https=)
CR (1) CR20190477A (https=)
DK (1) DK3596123T3 (https=)
ES (1) ES2975063T3 (https=)
FI (1) FI3596123T3 (https=)
HR (1) HRP20240469T1 (https=)
HU (1) HUE065999T2 (https=)
IL (1) IL269081B1 (https=)
LT (1) LT3596123T (https=)
MX (1) MX2019010974A (https=)
MY (1) MY208220A (https=)
PE (1) PE20191812A1 (https=)
PL (1) PL3596123T3 (https=)
RS (1) RS65351B1 (https=)
SG (1) SG11201908578YA (https=)
SI (1) SI3596123T1 (https=)
WO (1) WO2018167104A1 (https=)
ZA (1) ZA201904980B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11371066B2 (en) 2015-07-13 2022-06-28 Modular Genetics, Inc. Generation of acyl alcohols
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
KR102909650B1 (ko) * 2018-03-13 2026-01-08 터스크 테라퓨틱스 리미티드 종양 특이적 세포 고갈에 대한 항-cd25
CA3120096A1 (en) 2018-11-14 2020-05-22 Rubryc Therapeutics, Inc. Cd25 antibodies
EP3880698A4 (en) 2018-11-14 2022-11-30 RubrYc Therapeutics, Inc. MANIPULATED CD25 POLYPEPTIDES AND USES THEREOF
EP3972997A1 (en) * 2019-05-20 2022-03-30 Institut National de la Santé et de la Recherche Médicale (INSERM) Novel anti-cd25 antibodies
PL3932949T3 (pl) * 2019-06-10 2025-11-24 Shandong Boan Biotechnology Co., Ltd. Przeciwciało anty-cd25 i jego zastosowanie
BR112022020521A2 (pt) 2020-04-10 2023-03-07 Rakuten Medical Inc Compostos de corante ftalocianina, conjugados e métodos de uso dos mesmos
WO2021228218A1 (zh) 2020-05-14 2021-11-18 江苏恒瑞医药股份有限公司 抗cd25抗体、其抗原结合片段及其医药用途
US11124568B1 (en) * 2020-08-19 2021-09-21 Vitruviae LLC CD3/CD25 antibodies for neuro-immune diseases
EP4247497A1 (en) * 2020-11-20 2023-09-27 Institut National de la Santé et de la Recherche Médicale (INSERM) Anti-cd25 antibodies
WO2022106663A1 (en) * 2020-11-20 2022-05-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd25 antibodies
WO2022117572A2 (en) 2020-12-02 2022-06-09 Oncurious Nv An ltbr agonist in combination therapy against cancer
WO2022182483A1 (en) * 2021-02-02 2022-09-01 Rakuten Medical, Inc. Methods for local and systemic treatment of cancers, tumors and tumor cells
KR20230154012A (ko) 2021-03-01 2023-11-07 에프. 호프만-라 로슈 아게 신규 바이오마커 및 이의 용도
TW202319400A (zh) 2021-09-02 2023-05-16 瑞士商赫孚孟拉羅股份公司 用於治療aml之抗體
US20250257141A1 (en) 2022-04-26 2025-08-14 Hoffmann-La Roche Inc. Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist
CN115181182B (zh) * 2022-06-13 2024-03-29 南京融捷康生物科技有限公司 一种人源化的抗cd25的单域抗体及其应用
CA3260932A1 (en) * 2022-06-30 2024-01-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services CD25-SPECIFIC ANTIBODIES AND THEIR USES
CN119451978A (zh) 2022-07-01 2025-02-14 神经基因治疗公司 Neo-2/15变体及其用于优先刺激T调节细胞的用途
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
CN118240080A (zh) * 2022-12-22 2024-06-25 深圳市福元生物科技有限公司 一种cd25单域抗体、人源化抗体、及制备方法
EP4662238A1 (en) 2023-02-06 2025-12-17 F. Hoffmann-La Roche AG Combination therapy and uses thereof
CN116087499B (zh) * 2023-02-20 2023-10-31 深圳裕康医学检验实验室 一种癌样本的染色方法及试剂盒
CN120314588B (zh) * 2025-05-21 2025-10-17 成都蓉生药业有限责任公司 一种人免疫球蛋白抗体依赖性细胞介导的吞噬作用生物学活性的检测方法和检测试剂盒

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014145907A1 (en) * 2013-03-15 2014-09-18 Xencor, Inc. Targeting t cells with heterodimeric proteins

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US7438907B2 (en) 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25
WO2004063355A2 (en) 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
GB0409799D0 (en) * 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
GB0507696D0 (en) 2005-04-15 2005-05-25 Novartis Ag Organic compounds
WO2008002933A2 (en) 2006-06-26 2008-01-03 Macrogenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
CA2656700A1 (en) 2006-07-06 2008-01-10 Merck Patent Gesellschaft Mit Beschraenkter Haftung Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
AR062435A1 (es) 2006-08-18 2008-11-05 Xoma Technology Ltd Anticuerpo especifico prlr (receptor de prolactina) y sus usos
RU2391401C2 (ru) 2008-02-12 2010-06-10 Общество с ограниченной ответственностью "Лаборатория клеточного мониторинга" СПОСОБ ПОЛУЧЕНИЯ ПОПУЛЯЦИИ CD4+CD25+Foxp3+ Т-ЛИМФОЦИТОВ ЧЕЛОВЕКА ex vivo, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ
DK2356270T3 (da) 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
SG178925A1 (en) 2009-09-22 2012-04-27 Volker Sandig Process for producing molecules containing specialized glycan structures
PL3498730T3 (pl) * 2009-12-21 2026-04-07 Regeneron Pharmaceuticals, Inc. Humanizowane myszy fc gamma r
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
MX349662B (es) 2010-07-22 2017-08-08 Univ California Anticuerpos de antigenos antitumorales y metodos de uso.
EP2970488A2 (en) 2013-03-15 2016-01-20 AbbVie Biotechnology Ltd Anti-cd25 antibodies and their uses
MX2015012563A (es) 2013-03-15 2016-10-26 Abbvie Biotechnology Ltd Anticuerpos anti-cd25 y sus usos.
GB2526139A (en) 2014-05-15 2015-11-18 Biolnvent Internat Ab Medicaments, uses and methods
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
KR20220032642A (ko) 2016-04-07 2022-03-15 캔써 리서치 테크놀로지 리미티드 종양 특이적 세포 고갈을 위한 항 cd25 fc 감마 수용체 이중특이적 항체
US11077172B2 (en) 2016-11-08 2021-08-03 Delinia, Inc. IL-2 variants for the treatment of psoriasis
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
MX2020008768A (es) 2018-03-13 2020-10-08 Tusk Therapeutics Ltd Agentes anticuerpos anti-cd25.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014145907A1 (en) * 2013-03-15 2014-09-18 Xencor, Inc. Targeting t cells with heterodimeric proteins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A Pilot Study of IL-2Ra Blockade during Lymphopenia Depletes Regulatory T-cells and Correlates with Enhanced Immunity in Patients with Glioblastoma;John H.Sampson et al;《Plos One》;20120228;摘要、图6 *
Depletion of Regulatory T Cells Induces High Numbers of Dendritic Cells and Unmasks a Subset of Anti-Tumour CD8+CD11C+ PD-1 lo Effector T Cells;Nicolas Goudin et al;《PLOS ONE》;20160624;摘要 *
John H.Sampson et al.A Pilot Study of IL-2Ra Blockade during Lymphopenia Depletes Regulatory T-cells and Correlates with Enhanced Immunity in Patients with Glioblastoma.《Plos One》.2012, *
Preclinical evaluation of an anti-CD25 monoclonal antibody, 7G7/B6, armed with the beta-emitter, yttrium-90, as a radioimmunotherapeutic agent for treating lymphoma;Meili Zhang et al;Cancer Biother Radiopharm;第24卷(第3期);303-309 *

Also Published As

Publication number Publication date
IL269081A (en) 2019-11-28
MY208220A (en) 2025-04-24
LT3596123T (lt) 2024-03-25
FI3596123T3 (fi) 2024-04-17
CA3056506A1 (en) 2018-09-20
JP2024050684A (ja) 2024-04-10
AU2018233976B2 (en) 2025-03-20
EP3596123B1 (en) 2024-01-10
IL269081B1 (en) 2026-01-01
SI3596123T1 (sl) 2024-05-31
HUE065999T2 (hu) 2024-06-28
PL3596123T3 (pl) 2024-06-24
SG11201908578YA (en) 2019-10-30
CN110869388A (zh) 2020-03-06
EP3596123A1 (en) 2020-01-22
ZA201904980B (en) 2026-03-25
US11879014B2 (en) 2024-01-23
BR112019017017A2 (pt) 2020-04-14
DK3596123T3 (da) 2024-02-26
KR20190130137A (ko) 2019-11-21
PE20191812A1 (es) 2019-12-26
JP2020514363A (ja) 2020-05-21
US20200010554A1 (en) 2020-01-09
HRP20240469T1 (hr) 2024-07-19
NZ756984A (en) 2025-08-29
RS65351B1 (sr) 2024-04-30
MX2019010974A (es) 2020-08-03
AU2018233976A1 (en) 2019-10-31
CL2019002624A1 (es) 2020-04-03
ES2975063T3 (es) 2024-07-03
WO2018167104A1 (en) 2018-09-20
CR20190477A (es) 2020-01-07

Similar Documents

Publication Publication Date Title
CN110869388B (zh) 用于肿瘤特异性细胞消耗的Fc优化的抗CD25
US20240052044A1 (en) Non-blocking human ccr8 binders
RU2759970C2 (ru) БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К CD25 И Fc ГАММА-РЕЦЕПТОРУ ДЛЯ ЭЛИМИНАЦИИ ОПУХОЛЕСПЕЦИФИЧЕСКИХ КЛЕТОК
US20240076391A1 (en) Human ccr8 binders
JP7225135B2 (ja) 腫瘍特異的細胞枯渇のための化合物及び方法
WO2022003156A1 (en) Ccr8 non-blocking binders
CN112020515A (zh) 用于肿瘤特异性细胞清除的抗-cd25
US20240052045A1 (en) Murine cross-reactive human ccr8 binders
US20240018248A1 (en) An ltbr agonist in combination therapy against cancer
EP4151655A1 (en) Anti-cd25 antibodies, antigen-binding fragments thereof, and medical uses thereof
RU2839380C1 (ru) Fc-оптимизированные антитела к cd25 для истощения опухолеспецифических клеток
HK40016585A (en) Fc-optimized anti-cd25 for tumor specific cell depletion
HK40016585B (zh) 用於肿瘤特异性细胞消耗的fc优化的抗cd25
CN116917320A (zh) 鼠交叉反应性人ccr8结合剂
CN116888156A (zh) 非阻断性人ccr8结合剂
HK40101561A (zh) 人ccr8结合剂
HK40018012A (en) Compounds and methods for tumour-specific cell depletion
HK1262659A1 (en) Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletion

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40016585

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment